IBD Antibodies to anti-TNF therapy-consequences for IBD management

被引：2

作者：

van Deen, Welmoed K. ^{[1
]}

Hommes, Daniel W. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Ctr Inflammatory Bowel Dis, Los Angeles, CA 90095 USA

来源：

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2013年 / 10卷 / 08期

关键词：

INFLAMMATORY-BOWEL-DISEASE; INFLIXIMAB THERAPY; IMPACT;

D O I：

10.1038/nrgastro.2013.118

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Anti-TNF agents are effective drugs available for IBD treatment. However, antibody formation against these drugs hampers clinical effectiveness and increases risk of drug reactions. Knowledge on antibody kinetics and antibody testing is of critical importance to make well-informed decisions about starting, continuing, discontinuing and restarting of anti-TNF agents.

引用

页码：446 / 448

页数：4

共 9 条

[1] The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD [J].

Ben-Horin, S. ;

Mazor, Y. ;

Yanai, H. ;

Ron, Y. ;

Kopylov, U. ;

Yavzori, M. ;

Picard, O. ;

Fudim, E. ;

Maor, Y. ;

Lahat, A. ;

Coscas, D. ;

Eliakim, R. ;

Dotan, I. ;

Chowers, Y. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (06) :714-722

[2] The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful [J].

Ben-Horin, Shomron ;

Yavzori, Miri ;

Katz, Lior ;

Kopylov, Uri ;

Picard, Orit ;

Fudim, Ella ;

Coscas, Daniel ;

Bar-Meir, Simon ;

Goldstein, Itamar ;

Chowers, Yehuda .

GUT, 2011, 60 (01) :41-48

[3]

Garces S., ANN RHEUM DIS

[4] Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped [J].

Louis, Edouard ;

Mary, Jean-Yves ;

Vernier-Massouille, Gwenola ;

Grimaud, Jean-Charles ;

Bouhnik, Yoram ;

Laharie, David ;

Dupas, Jean-Louis ;

Pillant, Helene ;

Picon, Laurence ;

Veyrac, Michel ;

Flamant, Mathurin ;

Savoye, Guillaume ;

Jian, Raymond ;

Devos, Martine ;

Porcher, Raphael ;

Paintaud, Gilles ;

Piver, Eric ;

Colombel, Jean-Frederic ;

Lemann, Marc .

GASTROENTEROLOGY, 2012, 142 (01) :63-U201

[5] Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis [J].

Nanda, Kavinderjit S. ;

Cheifetz, Adam S. ;

Moss, Alan C. .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (01) :40-47

[6] Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease [J].

Steenholdt, C. ;

Palarasah, Y. ;

Bendtzen, K. ;

Teisner, A. ;

Brynskov, J. ;

Teisner, B. ;

Nielsen, C. H. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (12) :1172-1183

[7]

Steenholdt C, 2013, GASTROENTEROLOGY, V144, pS773

[8] Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis [J].

van Schouwenburg, Pauline A. ;

Rispens, Theo ;

Wolbink, Gerrit Jan .

NATURE REVIEWS RHEUMATOLOGY, 2013, 9 (03) :164-172

[9] Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient [J].

Vande Casteele, Niels ;

Gils, Ann ;

Singh, Sharat ;

Ohrmund, Linda ;

Hauenstein, Scott ;

Rutgeerts, Paul ;

Vermeire, Severine .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (06) :962-971

← 1 →